This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q3 boosted by strong rebound in sales and solid demand for PPE and COVID-19-related products.
Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View
by Zacks Equity Research
An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
ABC vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
Integra (IART) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Integra's (IART) third-quarter 2020 results reflect mixed segmental performance with strong recovery trends due to coronavirus-led business disruptions.
IDEXX (IDXX) Earnings Beat Estimates in Q3, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registered strong contribution from its CAG business in the third quarter despite pandemic-induced challenges.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up
by Zacks Equity Research
QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.
Boston Scientific (BSX) Q3 Earnings Top, Margins Decline
by Zacks Equity Research
Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.
Is West Pharmaceutical Services (WST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 13.86% and 7.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MCK or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Here's Why You Should Avoid Betting on Intuitive Surgical Now
by Zacks Equity Research
Intense competition in the global MedTech space and weak operational performance weighs on Intuitive Surgical (ISRG).
Veeva's Offering Chosen by Idorsia to Drive Digital Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) Commercial Cloud selected by Idorsia to enhance its digital field force in the United States, Japan and countries across Europe.
Top Ranked Growth Stocks to Buy for September 22nd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, September 22nd.
PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens
by Zacks Equity Research
PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Top Ranked Growth Stocks to Buy for September 18th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 18th.
Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (WST) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP.
Varian (VAR) Expands Presence With Germany's Ethos Order
by Zacks Equity Research
Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.
Here's Why You Should Retain AmerisourceBergen Stock Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches. However, stiff competition remains a woe.